Objective:To assess the clinical value of budesonide combined with salbutamol nebulized inhalation in patients who underwent thoracoscopic lobectomy.Methods:This retrospective control study included 172 patients who underwent thoracoscopic lobectomy from Jan.2023 to Jan.2024,and these patients were divided into control group(n=87)and experimental group(n=82)according to the presence or absence of salbutamol inhalation,the control group received budesonide and the experimental group received budesonide combined with salbutamol.The two groups received aerosol inhalation on the day before surgery and consecutive 3 d after surgery.Monitoring indicators included arterial blood gas analysis before surgery and at 3rd day after surgery,blood inflammatory markers(C-reactive protein,WBC count),and lung imaging.Results:There was no significant difference in general conditions inclu-ding age and gender between the two groups(P>0.05).The PaO2,PaCO2,C-reactive protein and WBC were not different between the two groups before operation,the PaO2 in the experimental group was significantly higher than that in the control group.After operation in the experimental group,the PaCO2,C-reactive protein levels,WBC count,and incidence of pneumonia were significantly lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusions:Budesonide combinedwithsalbuta-mol aerosol inhalation can effectively improve the pulmonary function,reduce the inflammatory response and risk of lung complications in patients after thoracoscopic lobectomy.
维普
万方数据